New approaches that combine regenerative medicine, autologous stem cells and genome engineering can repair rheumatic joints and produce self-regulating anti-inflammatory treatment to prevent future damage.
“We are already seeing improved outcomes and will have better outcomes coming in the future,” said Sharon A. Chung, MD, MAS.
Precision medicine shifts away from the more one-size-fits-all medicine models, and genomics offers an important tool for enabling personalized medicine.
“Probably the most important reason people with rheumatic diseases are not exercising is that they are not getting the message that physical activity is a good thing for them,” said Patricia Katz, PhD.
An ACR Convergence 2020 session saluted those who thrive while living with chronic illnesses and looked at the common traits in those populations.
The COVID-19 pandemic has accelerated the growth and overall acceptance of telemedicine in rheumatology and cemented its place as an important facet of care.
Empathy as a science needs to be elevated, exploited, and adopted—and researched—to provide patients the best care.
The second phase of the Accelerating Medicines Partnership is changing the way researchers look at rheumatoid arthritis, with deeper clinical, histological, and molecular data integrated across samples and between modalities.
The Rheumatoid Arthritis Practice Performance (RAPP) project launched to address care gaps in RA disease control, which often center around how disease activity is measured.
An ACR Convergence 2020 session described both the promises and problems of B-cell therapy.